Akari Therapeutics plc ADR (0.01 USD) AKTX
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $32.33 (+396.7% upside)
Key Stats
- Today's Range
- $6.51 – $7.69
- 50-Day Range
- $6.51 – $12.15
- 52-Week Range
- $3.02 – $42.80
- Volume
- 15K shs
- Average Volume
- 43K shs
- Market Cap
- $14.88 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 25.74%
- Days to Cover
- 4.55
About Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Related Stocks
Compare head-to-head: AKTX vs LLY·AKTX vs JNJ·AKTX vs ABBV·AKTX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.